ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

被引：220
作者：
Cang, Shundong [1 ]
Iragavarapu, Chaitanya [2 ,3 ]
Savooji, John [2 ,3 ]
Song, Yongping [4 ,5 ]
Liu, Delong [4 ,5 ]
机构：
[1] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou 450052, Peoples R China
[2] Westchester Cty Med Ctr, Dept Med, Valhalla, NY 10595 USA
[3] New York Med Coll, Valhalla, NY 10595 USA
[4] Zhengzhou Univ, Henan Canc Hosp, Zhengzhou 450052, Peoples R China
[5] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450052, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2015年 / 8卷
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-VIVO EFFICACY; BISPECIFIC ANTI-CD30/CD16A ANTIBODY; ACUTE MYELOID-LEUKEMIA; BH3 MIMETIC ABT-263; FAMILY PROTEINS; CELL-DEATH; HEMATOLOGICAL MALIGNANCIES; NUCLEAR EXPORT;
D O I：
10.1186/s13045-015-0224-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 ( venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.
引用
收藏
页数：8
相关论文
共 95 条
  • [1] Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo
    Ackler, S.
    Mitten, M. J.
    Chen, J.
    Clarin, J.
    Foster, K.
    Jin, S.
    Phillips, D. C.
    Schlessinger, S.
    Wang, B.
    Leverson, J. D.
    Boghaert, E. R.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2012, 167 (04) : 881 - 891
  • [2] ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
    Ackler, Scott
    Xiao, Yu
    Mitten, Michael J.
    Foster, Kelly
    Oleksijew, Anatol
    Refici, Marion
    Schlessinger, Sally
    Wang, Baole
    Chemburkar, Sanjay R.
    Bauch, Joy
    Tse, Christin
    Frost, David J.
    Fesik, Stephen W.
    Rosenberg, Saul H.
    Elmore, Steven W.
    Shoemaker, Alex R.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2008, 7 (10) : 3265 - 3274
  • [3] The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
    Ackler, Scott
    Mitten, Michael J.
    Foster, Kelly
    Oleksijew, Anatol
    Refici, Marion
    Tahir, Stephen K.
    Xiao, Yu
    Tse, Christin
    Frost, David J.
    Fesik, Stephen W.
    Rosenberg, Saul H.
    Elmore, Steven W.
    Shoemaker, Alexander R.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (05) : 869 - 880
  • [4] The Bcl-2 protein family: Arbiters of cell survival
    Adams, JM
    Cory, S
    [J]. SCIENCE, 1998, 281 (5381) : 1322 - 1326
  • [5] Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
    Akinleye, Akintunde
    Avvaru, Parthu
    Furqan, Muhammad
    Song, Yongping
    Liu, Delong
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [6] Ibrutinib and novel BTK inhibitors in clinical development
    Akinleye, Akintunde
    Chen, Yamei
    Mukhi, Nikhil
    Song, Yongping
    Liu, Delong
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [7] MEK and the inhibitors: from bench to bedside
    Akinleye, Akintunde
    Furqan, Muhammad
    Mukhi, Nikhil
    Ravella, Pavan
    Liu, Delong
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [8] [Anonymous], ASCO M ABSTR S
  • [9] [Anonymous], BLOOD
  • [10] [Anonymous], ASCO M ABSTR S
12345678910